Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 12/20 | 0.45 |
| ▸ | INSR | P06213 | 11/20 | 0.45 |
| ▸ | IGF1R | P08069 | 11/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | ROS1 | P08922 | 1/20 | 0.40 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30875688 | 1.00 | ALK (0.45) | ALKINSRIGF1RCDK7CDK9 | |
| SCHEMBL30223498 | 0.86 | ALK (0.48) | ALKINSRIGF1REGFRAURKA | |
| SCHEMBL24073495 | 0.86 | ALK (0.48) | ALKINSRIGF1REGFRAURKA | |
| SCHEMBL23933001 | 0.84 | INSR (0.47) | ALKINSRIGF1RCDK7CDK9 | |
| SCHEMBL30487106 | 0.84 | ALK (0.48) | ALKINSRIGF1RCDK7CDK9 | |
| SCHEMBL28949767 | 0.84 | ALK (0.48) | ALKINSRIGF1RCDK7CDK9 | |
| SCHEMBL29172320 | 0.84 | ALK (0.42) | ALKINSRIGF1RCDK7CDK9 | |
| SCHEMBL23153826 | 0.83 | ALK (0.47) | ALKINSRIGF1RCDK7CDK9 | |
| SCHEMBL17411151 | 0.82 | ALK (0.51) | ALKINSRIGF1RCDK7CDK9 | |
| SCHEMBL23153905 | 0.82 | EGFR (0.47) | ALKINSRIGF1RCDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| CN-117730083-A | Pyrimidine compounds as MAP4K1 inhibitors | 格兰马克专业公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | ALK 150/4885INSR 630/4885IGF1R 184/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | ALK 2067/4885INSR 3399/4885IGF1R 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.